Tag Archive for: METTL3 inhibition

STORM Therapeutics secures $56 Million Series C financing and doses first patient in Phase 2 sarcoma trial of STC‑15

/in

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation 16 April 2026, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, today announced a […]

Read more

STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications

/in

8 January 2026, Cambridge, UK, and San Diego, US: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration with Alida Biosciences Inc. (AlidaBio), a company at the forefront of epitranscriptomics and RNA modification analysis. STORM will utilize AlidaBio’s advanced EpiPlex® and EpiScout® next-generation sequencing […]

Read more
© Optimum Strategic Communications.